Search
Feed aggregator
Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS
Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS 4/5/2024
FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy
FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy 4/5/2024
Boehringer Ingelheim Cuts Staff Due to Low Humira Biosimilar Sales: Reuters
Boehringer Ingelheim Cuts Staff Due to Low Humira Biosimilar Sales: Reuters 4/5/2024
Novartis to File for Pluvicto Label Expansion After Promising Phase III Data
Novartis to File for Pluvicto Label Expansion After Promising Phase III Data 4/5/2024
U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.
AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and Rinvoq
AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and Rinvoq 4/26/2024
Pfizer Secures FDA Approval for Hemophilia B Gene Therapy, Launches Warranty
Pfizer Secures FDA Approval for Hemophilia B Gene Therapy, Launches Warranty 4/26/2024
Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline
Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline 4/26/2024
GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement
GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement 4/26/2024
Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost
Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost 4/26/2024
BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree
BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree 4/26/2024
Tessera Cuts Dozens of Jobs Following Positive Preclinical Results
Tessera Cuts Dozens of Jobs Following Positive Preclinical Results 4/26/2024
Biopharma Layoff Tracker 2024: BMS, CureVac, Tessera and More Cut Staff
Biopharma Layoff Tracker 2024: BMS, CureVac, Tessera and More Cut Staff 4/26/2024
FDA Decision Tracker: Pfizer’s First Gene Therapy Approved for Hemophilia B
FDA Decision Tracker: Pfizer’s First Gene Therapy Approved for Hemophilia B 4/26/2024
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the AB-1002 program. AB-1002 is an investigational one-time gene therapy that is administered to the heart with the intention of helping to promote the production of a constitutively active form of protein inhibitor 1 (I-1c) designed to block the action of protein phosphatase 1.
BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1
BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1 4/25/2024
Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20%
Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20% 4/25/2024
Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy
Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy 4/25/2024
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery 4/25/2024
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1 4/25/2024
World Pharma News
- U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
- AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
- Researchers publish final results of key clinical trial for gene therapy for sickle cell disease
- Optimal timing maximises Paxlovid benefits for treating COVID-19
- European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options